Hong Kong stock market anomaly | Sinobioway Biomed (01801.HK) rises more than 3%, reaches exclusive license agreement with Spero on IBI355, will start SjD Phase II clinical study early next year.
According to the Wisdom Finance and Economics APP, XinDa Bio (01801.HK) rose by more than 3%, as of the time of writing, it rose by 3.28% to HK$93, with a turnover of HK$1.01 billion.
Latest
